GeneGo and Genedata Integrates their Computational Systems
News Feb 14, 2006
GeneGo Inc. and Genedata AG have announced that their computational systems have been integrated to support a seamless data analysis workflow. The workflow supports target selection and validation as well as diagnostic and biomarker applications.
"Today, drug discovery scientists handle very complex "genome wide" experimental datasets," explained Julie Bryant, Vice President of Business Development at GeneGo Inc.
"To cope with such complexity they need a variety of analytical approaches and databases not available from any single source. Therefore, cooperation between computational biology specialists is logical and beneficial for end users."
GeneGo’s flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses.
Bryant added, "MetaCore can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively."
"Genedata’s open and scalable architecture provides a strong basis for integration with client and third party content," says Dr. Daniel Keesman, CEO of Genedata AG.
Expressionist is designed to enable omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore’s visualization tools to identify and prioritize pathways affected by disease.
The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their results in biological context, thus deriving maximum benefit from experimental data."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.